BCL2L1 and chronic myelogenous leukemia, BCR-ABL1 positive: DrugBank combines drug data with drug-target information thus enabling applications in cancer biology including in silico drug target discovery, drug design, drug interaction prediction, etc. In a study employing DrugBank, Augustyn et al. (156) evaluated potential therapeutic targets of achaete-scute homolog 1 (ASCL1) genes in lung cancers and reported unique molecular vulnerabilities for potential therapeutics, while Han et al. (157) determined synergistic combinations of drug targets in K562 chronic myeloid leukemia (CML) cells including BCL2L1 and MCL1 combination.